sFlt-1与PlGF在子痫前期及胎儿生长受限筛查、预测、诊断和监测中的临床价值
本文综述了母体PlGF、sFlt-1及sFlt-1/PlGF比值在单胎妊娠中筛查、短期预测、诊断和监测子痫前期及预测其他胎盘相关疾病的表现,并讨论了双胎妊娠中的预测价值。作者提出将这些血管生成因子检测更全面地整合到临床实践中。
要点
- 孕早期筛查单胎妊娠时,母体PlGF联合临床危险因素和超声标志物比现行方法更准确识别高危妇女。
- 孕中晚期sFlt-1/PlGF比值诊断和监测子痫前期的汇总敏感度和特异度优于PlGF,可排除检测后1-4周内发生子痫前期。
- sFlt-1/PlGF比值可预测双胎妊娠子痫前期,但需采用与单胎妊娠不同的 cut-off 值。
核心结论
- PlGF、sFlt-1及sFlt-1/PlGF比值可用于单胎和双胎妊娠胎盘相关疾病的筛查、诊断、预测和监测。
- 作者提出应将这些血管生成因子检测更全面地整合到临床实践中。
研究设计与样本
- 综述,总结现有知识,评估母体PlGF、sFlt-1及sFlt-1/PlGF比值在单胎妊娠中筛查子痫前期、短期预测子痫前期、诊断子痫前期、监测已确诊子痫前期及预测其他胎盘相关疾病的表现。
- 讨论PlGF及sFlt-1/PlGF比值在双胎妊娠中预测子痫前期的表现。
主要发现
- 孕早期筛查单胎妊娠时,母体PlGF联合临床危险因素和超声标志物比现行方法更准确识别高危妇女。
- 孕中晚期sFlt-1/PlGF比值诊断和监测子痫前期的汇总敏感度和特异度高于PlGF,可排除检测后1-4周内发生子痫前期。
- 确诊子痫前期后,重复测量sFlt-1和PlGF有助于监测病情进展,并可能为分娩最佳时机的临床决策提供信息。
- sFlt-1/PlGF比值有助于预测胎儿生长受限和早产,但血管生成因子与死产之间的关联尚不明确。
- sFlt-1/PlGF比值可预测双胎妊娠子痫前期,但需采用与单胎妊娠不同的sFlt-1/PlGF比值 cut-off 值以获得最佳性能。
临床怎么用
- 作者提出应将这些血管生成因子检测更全面地整合到临床实践中。
- 孕早期筛查单胎妊娠时,可将母体PlGF与临床危险因素和超声标志物联合使用。
- 孕中晚期可使用sFlt-1/PlGF比值诊断和监测子痫前期,并排除检测后1-4周内发生子痫前期。
- 确诊子痫前期后,可重复测量sFlt-1和PlGF以监测病情进展,并可能为分娩最佳时机的临床决策提供信息。
- 双胎妊娠预测子痫前期时,sFlt-1/PlGF比值应采用与单胎妊娠不同的 cut-off 值。
局限性
- 血管生成因子与死产之间的关联尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pre-eclampsia (PE) is characterized by placental and maternal endothelial dysfunction, and associated with fetal growth restriction (FGR), placental abruption, preterm delivery and stillbirth. The angiogenic factors soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) are altered in pregnancies complicated by placenta-related disorders. In this Review, we summarize the existing knowledge, examining the performance of maternal PlGF, sFlt-1 and the sFlt-1/PlGF ratio for screening PE, predicting development of PE in the short term, diagnosing PE, monitoring established PE and predicting other placenta-related disorders in singleton pregnancy. We also discuss the performance of PlGF and the sFlt-1/PlGF ratio for predicting PE in twin pregnancy. For first-trimester screening in singleton pregnancy, a more accurate way of identifying high-risk women than current practice is to combine maternal PlGF levels with clinical risk factors and ultrasound markers. Later in pregnancy, the sFlt-1/PlGF ratio has advantages over PlGF because it has a higher pooled sensitivity and specificity for diagnosing and monitoring PE. It has clinical value because it can rule out the development of PE in the 1-4-week period after the test. Once a diagnosis of PE is established, repeat measurement of sFlt-1 and PlGF can help monitor progression of the condition and may inform clinical decision-making regarding the optimal time for delivery. The sFlt-1/PlGF ratio is useful for predicting FGR and preterm delivery, but the association between stillbirth and the angiogenic factors is unclear. The sFlt-1/PlGF ratio can be used to predict PE in twin pregnancy, although different sFlt-1/PlGF ratio cut-offs from those for singleton pregnancy should be applied for optimal performance. In summary, PlGF, sFlt-1 and the sFlt-1/PlGF ratio are useful for screening, diagnosing, predicting and monitoring placenta-related disorders in singleton and twin pregnancy. We propose that tests for these angiogenic factors are integrated more fully into clinical practice.© 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Stepan H, Galindo A, Hund M, et al. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction. Ultrasound Obstet Gynecol. 2023. PMID: 35816445. doi:10.1002/uog.26032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。